Welcome to our dedicated page for Tandem Diabetes Care news (Ticker: $TNDM), a resource for investors and traders seeking the latest updates and insights on Tandem Diabetes Care stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tandem Diabetes Care's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tandem Diabetes Care's position in the market.
Rhea-AI Summary
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) plans to release its Q4 and full year 2023 results on February 21, 2024, followed by a conference call and webcast to discuss the financial and operating results. The webcast will be available on Tandem Diabetes Care’s Investor Center website, and an archive will be accessible for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.51%
Tags
-
Rhea-AI Summary
Abbott (ABT) and Tandem Diabetes Care (TNDM) have announced the integration of the FreeStyle Libre 2 Plus sensor with the t:slim X2 insulin pump in the U.S. This marks the first time that Tandem's Control-IQ technology is compatible with the 15-day continuous glucose monitoring (CGM) sensor, providing a hybrid closed-loop system for users in the United States.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
-
Rhea-AI Summary
ACRO (Association of Clinical Research Organizations) announced the election of Peyton Howell, Chief Operating & Growth Officer at Parexel, as Chair of the association effective Jan. 1, 2024. Lisa Moneymaker, Chief Technology Officer & Chief Product Officer at Saama, was elected Vice Chair. Mike Crowley, Chief Administrative Officer & General Counsel at Parexel, was elected Secretary, and Ari Feldman, Senior Vice President, Global Compliance and Strategy at Medidata Solutions, was re-elected Treasurer. ACRO also welcomed Advarra and YPrime as its newest members, reflecting the association's continued evolution in representing CROs and clinical technology companies that support drug development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.22%
Tags
Rhea-AI Summary
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) has announced the launch of Tandem Source, a diabetes management platform for insulin pump users and healthcare providers. This platform consolidates various features into one central location, providing comprehensive data reporting and easy access to therapy data, supply reordering, and pump software updates. The platform has received positive feedback from early adopters in the United States and is expected to be available internationally by 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.22%
Tags
-
News
Rhea-AI Summary
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) launches updated t:slim X2™ insulin pump software with Dexcom G7 Continuous Glucose Monitoring (CGM) integration in the United States. This marks the first automated insulin delivery system in the world to feature Dexcom’s most advanced CGM technology. The integration allows t:slim X2 insulin pump users to spend more time in closed loop with little to no wait time between Dexcom G7 CGM sensor sessions. The Dexcom G7 is 60 percent smaller than its predecessor, offers improved accuracy, a 30-minute sensor warmup time, and a 12-hour grace period to replace finished sensors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.06%
Tags
-
Rhea-AI Summary
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) will present a company update at several investor conferences. The presentations will be webcast live and archived for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.21%
Tags
Rhea-AI Summary
Tandem Diabetes Care, Inc. appoints Mark Novara as Executive Vice President and Chief Commercial Officer. Novara brings extensive global healthcare experience and will join the leadership team effective November 13, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.37%
Tags
-
Rhea-AI Summary
Tandem Diabetes Care reported its financial results for Q3 2023, with an 11% increase in the worldwide installed base of in-warranty customers. They also published a prospective study demonstrating the benefits of their t:slim X2 with Control-IQ technology. The company commenced the limited release of Tandem Mobi in the US and achieved full US healthcare provider availability of Tandem Source. They have $498.2 million in cash, cash equivalents, and short-term investments as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.37%
Tags
-
Rhea-AI Summary
Tandem Diabetes Care to release Q3 2023 results on November 1, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.21%
Tags
Rhea-AI Summary
Tandem Diabetes Care to present company update at investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
Tandem Diabetes Care, Inc.
Nasdaq:TNDM
TNDM Rankings
TNDM Stock Data
3.31B
59.86M
0.63%
110.34%
14.19%
Surgical and Medical Instrument Manufacturing
Manufacturing
United States of America
San Diego
About TNDM
tandem diabetes care, inc. is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. the company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. tandem manufactures and sells the t:slim x2™ insulin pump, the only pump capable of remote feature updates using a personal computer, and the t:flex® insulin pump, the first pump designed for people with greater insulin requirements. tandem is based in san diego, california. safety information please note that this account is not intended to be used for product support or medical advice. if you are having a medical emergency, please dial 911. if you are having an issue with one of our products and need immediate assistance, please call our 24 hour customer support team at 877-801-6901 and press 1 twice. tandem insulin pumps are intended for the subcutan